RECORD // Company

Mineralys Therapeutics, Inc.

Built 2026-11-22T00:21:10Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (4)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • MINERALYS THERAPEUTICS, INC. · Ct business · same registered legal name as 'Mineralys Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Mineralys Therapeutics Inc. · Ctgov · same registered legal name as 'Mineralys Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Mineralys Therapeutics, Inc. · East licences · same registered legal name as 'Mineralys Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • MINERALYS THERAPEUTICS, INC. · Ny corps · same registered legal name as 'Mineralys Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

5 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-04 · accession 0001933414-26-000144

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-57,328,0003 months ended 2026-09-3010-Q2026-11-040001933414-26-0001442026-11-22 00:21 UTCReport an error
Interest expense$3,188,0003 months ended 2026-09-3010-Q2026-11-040001933414-26-0001442026-11-22 00:21 UTCReport an error
Cash and cash equivalents$101,273,000at 2026-09-3010-Q2026-11-040001933414-26-0001442026-11-22 00:21 UTCReport an error
Debt due in the next 12 months$50,000at 2026-09-3010-Q2026-11-040001933414-26-0001442026-11-22 00:21 UTCReport an error
Debt due in year 2$50,000at 2026-09-3010-Q2026-11-040001933414-26-0001442026-11-22 00:21 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001933414
Ticker
MLYS
EIN
841966887
CUSIP
603170101
Record ID
sx:sec:0001933414

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

30 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-04SEC EDGAR company profile2026-11-22 00:21 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-04SEC EDGAR company profile2026-11-22 00:21 UTCReport an error
Fiscal year end (MMDD)12312026-11-04SEC EDGAR company profile2026-11-22 00:21 UTCReport an error
Business address150 N. RADNOR CHESTER ROAD, SUITE F200, RADNOR, PA2026-11-04SEC EDGAR company profile2026-11-22 00:21 UTCReport an error
ExchangesNasdaq2026-11-04SEC EDGAR company profile2026-11-22 00:21 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-154,651,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:21 UTCReport an error
Total assets (at 2025-12-31)$661,806,0002025-12-3110-K, XBRL Assets2026-11-22 00:21 UTCReport an error
Stockholders' equity (at 2025-12-31)$646,693,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:21 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$172,921,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:21 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-142,416,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:21 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$15,0002025-12-3110-K, XBRL PaymentsToAcquireProductiveAssets2026-11-22 00:21 UTCReport an error
Form D total offering amount (D filed 2022-06-13)$117,999,9942022-06-13D2026-11-22 00:21 UTCReport an error
Form D total amount sold (D filed 2022-06-13)$117,999,9942022-06-13D2026-11-22 00:21 UTCReport an error
Form D industry groupPharmaceuticals2022-06-13D2026-11-22 00:21 UTCReport an error
Form D revenue rangeDecline to Disclose2022-06-13D2026-11-22 00:21 UTCReport an error
Form D date of first sale2022-06-012022-06-13D2026-11-22 00:21 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-04)On November 4, 2026, Mineralys Therapeutics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2026 and provided a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as…2026-11-04SEC EDGAR 8-K 0001933414-26-000142 (text as filed, excerpt)2026-11-22 00:21 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-10-29)Mineralys Therapeutics, Inc. (the Company) and Tanabe Pharma Corporation (Tanabe) were previously parties to that certain License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023, May 29, 2025 and June 2, 2026 (as amended, the License Agreement), pursuant to which Tanabe had granted to the Company an exclusive, worldwide, royalty-free, sublicensable, perpetual and irrevocable license to certain intellectual property rights to develop and commercialize lorundrostat. Under the License Agreement, the Company had remaining obligations to pay Tanabe commercial milestone payments of up to $255.0 million in the aggregate upon first commercial sale of lorundrostat and…2026-10-29SEC EDGAR 8-K 0001933414-26-000136 (text as filed, excerpt)2026-11-22 00:21 UTCReport an error
8-K Item 1.02, Termination of a Material Definitive Agreement (filed 2026-10-29)The information provided in Item 1.01 of this Current Report on Form 8-K regarding the termination of the License Agreement is incorporated by reference into this Item 1.02. The Company did not incur any material early termination penalties in connection with the termination of the License Agreement.2026-10-29SEC EDGAR 8-K 0001933414-26-000136 (text as filed, excerpt)2026-11-22 00:21 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-11)On August 11, 2026, Mineralys Therapeutics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended June 30, 2026 and provided a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended…2026-08-11SEC EDGAR 8-K 0001933414-26-000112 (text as filed, excerpt)2026-11-22 00:21 UTCReport an error
Largest institutional holder #1 (13F as filed): Catalys Pacific, LLC$213,245,5492026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:21 UTCReport an error
Largest institutional holder #2 (13F as filed): RA CAPITAL MANAGEMENT, L.P.$207,550,3952026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:21 UTCReport an error
Largest institutional holder #3 (13F as filed): BlackRock, Inc.$158,832,2882026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:21 UTCReport an error
Largest institutional holder #4 (13F as filed): SAMSARA BIOCAPITAL, LLC$158,400,0662026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:21 UTCReport an error
Largest institutional holder #5 (13F as filed): FMR LLC$121,725,3822026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:21 UTCReport an error
Largest institutional holder #6 (13F as filed): STATE STREET CORP$111,741,3392026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:21 UTCReport an error
Largest institutional holder #7 (13F as filed): DEERFIELD MANAGEMENT COMPANY, L.P.$106,786,8402026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:21 UTCReport an error
Largest institutional holder #8 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$74,377,6552026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:21 UTCReport an error
Largest institutional holder #9 (13F as filed): Laurion Capital Management LP$67,615,9812026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:21 UTCReport an error
Largest institutional holder #10 (13F as filed): ORBIMED ADVISORS LLC$56,935,8942026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:21 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.